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Abstract
Background: Elevated numbers of regulatory T cells (Tregs) have been implicated in certain cancers. Depletion of
Tregs has been shown to increase anti-tumor immunity. Tregs also play a critical role in the suppression of
autoimmune responses. The study of Tregs has been hampered by a lack of adequate surface markers. Leucine Rich
Repeat Containing 32 (LRRC32), also known as Glycoprotein A Repetitions Predominant (GARP), has been
postulated as a novel surface marker of activated Tregs. However, there is limited information regarding the
processing of LRRC32 or the regulatory phenotype and functional activity of Tregs expressing LRRC32.
Results: Using naturally-occurring freshly isolated Tregs, we demonstrate that low levels of LRRC32 are present
intracellularly prior to activation and that freshly isolated LRRC32
+ Tregs are distinct from LRRC32
- Tregs with respect
to the expression of surface CD62L. Using LRRC32 transfectants of HEK cells, we demonstrate that the N-terminus
of LRRC32 is cleaved prior to expression of the protein at the cell surface. Furthermore, we demonstrate using a
construct containing a deleted putative signal peptide region that the presence of a signal peptide region is
critical to cell surface expression of LRRC32. Finally, mixed lymphocyte assays demonstrate that LRRC32
+ Tregs are
more potent suppressors than LRRC32
- Tregs.
Conclusions: A cleaved signal peptide site in LRRC32 is necessary for surface localization of native LRRC32
following activation of naturally-occurring freshly-isolated regulatory T cells. LRRC32 expression appears to alter the
surface expression of activation markers of T cells such as CD62L. LRRC32 surface expression may be useful as a
marker that selects for more potent Treg populations. In summary, understanding the processing and expression of
LRRC32 may provide insight into the mechanism of action of Tregs and the refinement of immunotherapeutic
strategies aimed at targeting these cells.
Background
Leucine Rich Repeat Containing 32 (LRRC32), also
known as Glycoprotein A Repetitions Predominant
(GARP), is a member of the leucine rich repeat family
that exhibits evolutionary similarity to Toll-like recep-
tors [1]. It was initially localized to chromosome 11q13-
14 but has since been further defined and mapped to
the 11q13.5-14 region [2-5]. The Lrrc32 gene consists of
two coding exons and is expressed as two different tran-
scripts, 4.4 and 2.8 kb in length [3]. The homologous
mouse gene has been found in the 7F chromosomal
region and shares high sequence homology to human
LRRC32 [2,6]. The homologous gene in grass carp (Cte-
nopharyn-godonidellus) shares 37% homology with
human Lrrc32, and it has been found to contain tran-
scription factor binding sites for AP1, IRF-1, IRF4, IRF-
7, and NFAT, which are critical for the expression of
many cytokines, suggesting a role for LRRC32 in the
immune system [7].
Lrrc32 has been shown, via Northern blot, to be
expressed in placenta, lung, kidney, heart, liver, skeletal
muscle, and pancreas but not brain [3]. Furthermore,
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and appears to mediate FoxP3 expression, enabling Tregs
to suppress effector cell activation [8-10]. With respect
to the structural aspects of LRRC32, a sequence analysis
of the human 662 amino acid protein product initially
suggested that it was almost entirely extracellular, with
20 leucine rich repeats in the extracellular portion of
the protein followed by a hydrophobic stretch of pro-
teins thought to be a transmembrane domain, followed
by a short cytoplasmic domain consisting of 15 amino
acids [3]. Sequence analysis by SignalP 3.0 revealed a
putative N terminal signal peptide with a likely cleavage
site after residue 17 of the pro-peptide. Surface localiza-
tion of this protein in transfected cells has been con-
firmed [8,9,11]. N-linked glycosylation has also been
reported to play a role in post-translational processing
of this protein [3].
LRRC32 is expressed on the surface of expanded Tregs,
and IL-2-expanded LRRC32-positive CD25
hi cells are
more suppressive than their IL-2-expanded LRRC32-
negative counterparts [10]. Inhibition of LRRC32 expres-
sion using lentiviral or siRNA strategies in expanded
Treg populations results in decreased suppressive capa-
city of the targeted cells [10]. The studies summarized
above used previously-expanded Tregs. Therefore, they
do not address the suppressive capacity of freshly iso-
lated naturally-occurring LRRC32
+ and LRRC32
- subpo-
pulations of CD25
hi regulatory cells. Although addition
of TGF-b to LRRC32
-CD25
- cells induced FoxP3 expres-
sion, LRRC32 was not upregulated, and cells treated in
this manner were unable to suppress the proliferation of
T effectors, suggesting that the upregulated expression
of FoxP3 was not sufficient to confer suppressive capa-
city on effector cells [10]. Furthermore, over-expression
of FoxP3 on activated CD4
+ T cells did not induce
expression of LRRC32 on the cell surface [10]. Finally, it
has also recently been reported that LRRC32 binds
latency-associated protein (LAP) and that surface
expression of LAP, in turn, is upregulated on activated
Tregs in conjunction with LRRC32 upregulation [11-13].
As previously reported, Tregs may also use cell-surface
bound transforming growth factor beta (TGF-b)t o
directly inhibit Teff growth in a cell to cell contact
dependent manner [14].
Naturally-occurring Tregs are currently defined by the
phenotypic expression of numerous surface markers
including CD4, CD25, CD127, CD49, GITR, CTLA4,
and the intracellular transcription factor FoxP3 [15-22].
S i n c en os i n g l em a r k e ri d e n t i f i e st h eT reg subset, the
potential use of LRRC32 as an additional surface marker
for potent Tregs is of interest. We surmised that LRRC32
surface expression on Tregs might have utility for the
selection of Tregs for functional studies as well as differ-
entiation and activation studies. Although previous
studies have looked at the functional suppressive capa-
city of Tregs that were expanded with cytokines such as
IL-2, we chose to study the suppressive capacity of natu-
rally-occurring freshly isolated activated Tregs in the
absence of long-term culture or repeated rounds of
stimulation.
A previous study utilized a signal peptide deletion
construct to show that naive T cells transfected with an
LRRC32 signal peptide deletion construct lacked protein
upregulation of CD25, CD62L, and FoxP3 compared to
transfection with wildtype LRRC32 [8]. This study uti-
lized GFP-tagged signal peptide deletion constructs that
were transfected into HEK293 cells to study the contri-
bution of signal peptide to surface expression of
LRRC32 [8]. Surface expression was only evaluated by
phase contrast and DAPI confocal microscopy of single
cells. These images suggested that some of the LRRC32
signal traffic to the cell surface, in contrast with our pre-
diction. Because experiments by Wang et al.w e r e
unclear and did not conclusively show that deletion of
the signal peptide region affects cell surface expression
of conformationally intact native LRRC32 using antibo-
dies capable of recognizing the extracellular domain of
LRRC32, we decided to characterize the functional and
phenotypic properties of Tregs expressing LRRC32 by
immunuohistochemistry.
We show that LRRC32 is a marker for a more potent
subset of freshly isolated activated Tregs.W ef u r t h e r
characterize Treg subsets with respect to the expression
of other Treg markers in the context of LRRC32 expres-
sion. We examine the intracellular processing of
LRRC32 and conclusively demonstrate in multiple cells
that the N-terminal portion of LRRC32 is cleaved prior
to expression of the protein on the cell surface and that
cleavage of this signal peptide is necessary for transloca-
tion of the mature protein to the cell surface. Further-
more, we directly confirm, using antibodies specific for
native LRRC32, that the signal peptide region of
LRRC32 is critical for its surface expression. We also
demonstrate low levels of intracellular LRRC32 prior to
activation via the T cell receptor (TCR) and CD28, sug-
gesting that low levels of LRRC32 are sequestered intra-
cellularly and that T cell activation is necessary for the
synthesis and surface expression of LRRC32. Expression
of LRRC32 may enhance Treg function. Therefore,
refinement of immunotherapeutic strategies aimed at
targeting LRRC32 may improve strategies for Treg isola-
tion and yield more potent Tregs.
Methods
Isolation of CD4
+ cells
Peripheral blood was donated by healthy human volun-
teers coordinated by the Skin Diseases Research Center
at University Hospitals Case Medical Center. Signed
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to their participation in the study. The study protocol
was approved by the Institutional Review Board of Uni-
versity Hospitals Case Medical Center. Peripheral blood
mononuclear cells (PBMCs) were prepared by Histopa-
que-1077 (Sigma-Aldrich) density gradient separation in
accordance with manufacturer’s protocols. Negatively
selected CD4
+ T cells were purified using magnetic bead
technology, per manufacturer’si n s t r u c t i o n s( M i l t e n y i
Biotec).
Generation of Constructs
Plasmid DNA encoding the cDNA of full length human
LRRC32 protein (TrueClone pCMV6-XL6 Human Full-
Length cDNA Clones, OriGene) was used to transform
competent One Shot Top 10 E. coli (Invitrogen), accord-
ing to the manufacturer’s instructions. Selection of posi-
tive clones was performed on kanamycin (Invitrogen)
LB agar plates. Plasmids were recovered and purified
using a Qiaquick MaxiPrep purification kit (Qiagen).
The following primers encoding regions flanking the
entire Lrrc32 sequence were used to amplify the Lrrc32
cDNA sequence via PCR and insert a TOPO cloning
site for pENTR/D-TOPO (Invitrogen): pCMV6-LRRC32
reverse (TTAG GCTTTATACTGTTGGTTAAACTT),
pCMV6-LRRC32 reverse readthrough (GGCTTTATA
CTGTTGGTTAAACTTCTG), and pCMV6-LRRC32
forward (CACCATGAGACCCCAGA TCCTGCT).
The following 1x PCR buffer conditions were used:
AccuPrime Pfx 1x reaction buffer (Invitrogen), 10 mM
of forward primer, 10 mM of reverse or reverse read-
through primer, 50 ng of template DNA, and 1 unit of
AccuPrime Pfx DNA (Invitrogen). PCR conditions were
as follow: initial denaturation at 95 C for 2 minutes fol-
lowed by 36 cyles of denaturation, annealing, and exten-
sion at 95 C, 55 C, and 68 C for 15 s, 30, and 2
minutes, respectively, followed by final extension at 68
C for 30 minutes.
PCR products containing the Lrrc32 sequence derived
from reactions utilizing either the forward and reverse
primers or forward and reverse readthrough primers
were then inserted into pENTR/D-TOPO, per the man-
ufacturer’s instructions to generate two different respec-
tive constructs: pENTR/D-TOPO/C-terminus LRRC32
(containing a stop codon at the end of the LRR32
sequence) and pENTR/D-TOPO/N-terminus LRRC32
(lacking a stop codon at the end of the LRR32
sequence). One Shot Top 10 E. coli were transformed as
described above, and positive clones were selected using
LB Agar plus kanamycin plates. Plasmid DNA was iso-
lated using a Qiaquick MiniPrep (Qiagen) kit, and M13
forward and reverse primers were subsequently used to
facilitate sequencing of the inserted PCR products
within each of the screened and purified plasmids via
t h eS e q u e n c i n gC o r ea tC a s eW e s t e r nR e s e r v eU n i v e r -
sity. The reported sequence was aligned with the
reported cDNA sequence of LRRC32 obtained from Ori-
Gene using the Vector NTI (Invitrogen) software sys-
tem, and sequence alignments were then confirmed
prior to further utilization of the LRRC32 sequence-veri-
fied plasmids.
LRRC32 sequence-verified pENTR/D-TOPO/N-termi-
nus LRRC32 or pENTR D-TOPO/C-terminus LRRC32
plasmids were then used in a Gateway (Invitrogen) clon-
ing strategy utilizing either the Vivid Colors pcDNA6.2/
N-EmGFP or pcDNA6.2/C-EmGFP (Invitrogen) as des-
tination vectors, per manufacturer’s instructions to gen-
erate two products, pcDNA6.2 N-terminus LRRC32/C-
EmGFP and pcDNA6.2 C-terminus LRRC32/N-EmGFP,
encoding “C-GFP/LRRC32” and “N-GFP/LRRC32”
respect-ively. Products were used to transform One Shot
Top 10 E. coli., and selection of positive clones was per-
formed on LB Agar plus ampicillan plates. Purified plas-
mids derived from expanded clones were screened again
using restriction enzyme analysis to confirm expected
restriction sites in the sequence.
To generate an Lrrc32 signal peptide deletion con-
struct, we utilized the newly created pcDNA6.2 C-termi-
nus LRRC32/N-EmGFP vector as a template for PCR
amplification. The pCMV6-LRRC32 reverse readthrough
primer, described above, as well as a newly created
pCMV6-LRRC32ΔSP primer (CACCATGGCACAACA
CCAAGACAAAGT), designed to anneal optimally to
bases just distal to the presumed signal peptide cleavage
site of LRRC32, were utilized to generate a PCR product
containing the Lrrc32 sequence without a putative signal
peptide sequence. The PCR product was then inserted
into pENTR/D-TOPO, and an identical strategy as that
described above was utilized to create a pcDNA6.2 N-
terminus LRRC32ΔSP/C-EmGFP product coding for a
LRRC32 signal peptide deletion construct ("C-GFP/
LRRC32ΔSP”)t a g g e da tt h eC - t e r m i n u se n dw i t hG F P .
The primer “C-EmGFP TOPO Internal Rev”
(TGAACTTCAGGGTCAGCTTGCCGTA) was utilized
to confirm that the GFP and LRRC32 (minus the signal
peptide) coding regions were in frame.
Realtime PCR Analysis
RNA was extracted using the RNeasy kit (Qiagen). 100
ng of total RNA was then processed using the Super-
Script III First-Strand Synthesis System (Invitrogen) and
random hexamers as primers and to generate cDNA,
per manufacturer’s protocol. The following gene expres-
sion assays were subsequently used for RT-PCR analysis:
FoxP3 (HS00203958_ml, Applied Biosystems), LRRC32
(HS00194136_ml, Applied Biosystems), 18S (HS999
99901_sl, Applied Biosystems), and GFP (Applied Bio-
systems). RT-PCR analysis was performed in accordance
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Biosystems) with an Applied Biosystems 7500 Realtime
PCR system, and StepOne 2.0 analysis software was
used to analyze the data.
Transfection of and Establishment of Stable Cell Lines
HEK293 cells (ATCC, Manassas, VA) were transfected
with plasmid containing either pENTR D-TOPO/C-ter-
minus LRRC32 ("C-GFP/LRRC32”)o rN - t e r m i n u s
LRRC32 ("N-GFP/LRRC32”), utilizing a 3:1 ratio of
FuGene 6 (microliters, Roche) to plasmid (micrograms)
according to the manufacturer’s protocol. Stable trans-
fectants were selected using blastocidin (Invitrogen)
according to the manufacturer’s protocol, and individual
cells were sorted based upon their GFP expression using
a FACS Aria cell sorting system (Becton Dickinson) into
96 well plates. Stable clones expressing N-GFP/LRRC32,
C-GFP/LRRC32, or C-GFP/LRRC32ΔSP were thus
derived from sorted single cells with the highest GFP
expression.
Biotinylation of cell surface proteins,
Immunoprecipitation and Western Blotting
Sulfo-NHS-LC-Biotin (#21327, Pierce) was utilized to
label cell surface proteins, in accordance with the manu-
facturer’s protocol. Biotinylated cells were lysed in Glo
Lysis Buffer (#E266A, Promega) per manufacturer proto-
cols. GFP-tagged proteins derived from the cell lysates
were then immunoprecipitated with mouse anti-GFP
(#A11120, Invitrogen) using an ExactaCruz E system,
per manufacturer’s instructions (#sc-45042, Santa Cruz
Biotechnology). Immunoprecipitated proteins were elec-
trophoresed on precast NuPAGE gels (Invitrogen) with
their corresponding premade MOPS SDS buffers (Invi-
trogen). Proteins were transferred to polyvinylidene
difluoride (PVDF) membranes (#LC2002, Invitrogen),
per manufacturer’s protocol, for subsequent probing
using anti-GFP antibody (#A11121, Invitrogen; #33-
2600, Zymed) or isotype control antibody (Invitrogen).
A SuperSignal PICO (Pierce) kit containing HRP-
coupled rabbit anti-mouse antibody was used for detec-
tion of GFP-tagged proteins. HRP-coupled goat polyclo-
n a lt om o u s eI g G( # a b 6 7 8 9 ,A b c a m )w a sa l s ou s e dt o
recognize bound murine antibody. Rabbit polyclonal
antibodies to Foxp3 (#ab10563, Abcam) were used to
probe for human FoxP3 on membranes, and HRP-
coupled goat polyclonal antibodies to rabbit IgG were
used to recognize bound rabbit antibodies. For detection
of biotinylated proteins, streptavidin-HRP (#21126,
Pierce) was utilized.
For the assessment of cellular LRRC32 expression in
the context of the signal peptide deletion constructs, an
identical protocol as above was used except that cells
were lysed using the M-PER Mammalian Protein
Extraction Reagent (#78503, Pierce). Plato-1(ALX-804-
867-C100, Axxora) was used to detect LRRC32, and the
Pierce Fast Western Blot Kit (#35050, Pierce) was used
to visualize immunoblots.
Flow Cytometry Analysis of CD4
+ Cells
CD4
+ cells were placed in culture media (RPMI, 10%
FBS, penicillin, streptomycin, L-glutamine, and b-mer-
captoethanol) and rested overnight in 96-well plates or
stimulated in anti-CD3-coated plates supplemented with
soluble murine anti-human CD28 (1 microgram/ml,
Becton Dickenson) [23]. Cells were subsequently stained
using antibodies to CD25 (clone 2A3, Becton Dicken-
son), LRRC32 (Axxora), FoxP3 (eBioscience), and a
panel of antibodies specific for CD69 (Becton Dickin-
s o n ) ,C D 6 2 L( B e c t o nD i c k i n s o n ) ,G I T R( R&DB i o s y s -
tems), CTLA4 (Becton Dickinson), HLA-DR (Becton
Dickinson), and CD45RO (Becton Dickinson), per man-
ufacturer’s protocol for staining cells for flow cytometry
(eBioscience). Cells were fixed and then permeabilized
using a fixation permeabilization kit (eBioscience) after
staining surface antigens in order to study the intracel-
lular expression of certain proteins (LRRC32, FoxP3).
For assessment of intracellular expression of LRRC32,
permeabilized cells were incubated with 2.5 micro-
grams/ml of IgG2b control isotype antibody (Invitrogen)
for 30 minutes prior to incubation with labeled anti-
L R R C 3 2a n t i b o d yt od e c r e a s en o n - s p e c i f i cb i n d i n g .I s o -
type controls were performed for compensation. Cells
were analyzed on a Becton Dickenson LSR II flow cyt-
ometer. In all instances, with the exception of the
mRNA studies, CD25
hi cells represented the top 5% of
CD25
+ cells. In the case of the mRNA studies in which
CD25
hi and
mid populations were identified, CD25
hi++
cells represented the top 1.5% of CD25
+ cells, and
CD25
hi+ cells represented the next highest 2-3% of
CD25
+ cells as depicted in Figure 1a.
Expansion and stimulation of Tregs
CD4
+ cells were isolated as described above. Subse-
quently, the cells were stained with anti-CD25 (Becton
Dickenson). The top 5% of CD25
hi cells were sorted,
and cells were expanded and stimulated for 2 weeks
using beads coated with anti-CD3 and anti-CD28
according to manufacturer directions (Dynabeads
Human Treg Expander, Catalog #111.29, Invitrogen)
prior to characterization. Unstimulated sorted CD25
hi
cells derived from isolated CD4
+ cells from the same
patient were used as a control for unsimulated Tregs.
Proliferation Assay
Negatively selected CD4
+ cells were stained with anti-
C D 2 5 ,a n dt h et o p5 %o fC D 2 5c e l l s( C D 2 5
hi)w e r e
sorted using a Becton Dickenson FACS Aria cell sorter.
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Page 4 of 15Figure 1 Lrrc32 mRNA is preferentially expressed in naturally-occurring freshly-isolated non-expanded human Tregs but is not
observed on the surface of these cells. a) T cell sorting gates based upon CD25 surface expression. b) Lrrc32 mRNA expression comports with
Foxp3 mRNA expression and CD25 surface expression, and Lrrc32 mRNA is preferentially expressed in Tregs, compared to Teffs. Relative expressions
of 18SrRNA-normalized Foxp3 and Lrrc32 genes were determined using real-time PCR. Data summarize four independent experiments. Results are
expressed as the mean ± SEM. *p = 0.01 compared to CD25
mid cells, **p = 0.005 compared to CD25
mid cells. c) Flow cytometric analysis of
freshly-isolated activated CD4
+ human T cells shows that the CD25
hi subgroup (composed of the CD25hi+ and CD25hi++ subgroups denoted in
figure 1b) demarcating Tregs expresses LRRC32 on the cell surface (top right panel) but that the CD25
- subgroup demarcating Teffs expresses
negligible amounts of LRRC32 on the cell surface (bottom right panel). Analysis strategy is indicated via the arrows. d) Flow cytometric analysis
of sorted resting CD4
+ human Tregs shows that they lack surface expression of LRRC32 protein (top left panel). However, after permeabilization of
the cell membrane, a low expression of LRRC32 protein can be observed intracellularly (top right panel). After activation of the sorted Tregs with
aT reg expansion kit, LRRC32 can be seen on the surface of these activated Tregs (bottom left panel), and evidence of intracellular expression of
LRRC32 can also be observed after permeabilization of the cell membrane (bottom right panel).
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coated plates (Becton Dickinson) supplemented with
soluble murine anti-human CD28 (Pharmingen) as
described above. CD25
- effector T cells were maintained
in culture media. Stimulated CD25
hi cells were subse-
quently stained with antibody specific for LRRC32
(Axxora), and LRRC32
+ and LRRC32
- subpopulations
were further sorted. LRRC32
+ positive and LRRC32
-
Treg subpopulations were then co-cultured with CD25
-
effector T cells plus irradiated allogeneic antigen pre-
senting cells (APCs) at various Treg:Teff ratios ranging
from 1:1 to 1:16 in a 96 well round bottomed tissue cul-
ture plate (Costar) as previously described [23]. Each
well contained 20,000 Teffs and 50,000 APCs which had
been previously irradiated at 3,000 Rad. Mixed lympho-
cytes were cultured for 6 days, and cells were pulsed
with 1 μCi/well [
3H]thymidine (NET-027A, Perkin-
Elmer) for the last 16 h. Proliferation was measured
using a TopCount scintillation counter (Perkin-Elmer).
Maximum proliferation was calculated by measuring the
proliferation of cells in wells lacking Tregs and contain-
ing only Teffs and APCs. Background proliferation was
ascertained via measurement of proliferation of Teffs
only in the absence of APCs.
Statistical Analysis
Statistical analysis was performed using Student’stt e s t
(surface phenotype analysis) or a three way ANOVA
(mixed lymphocyte response assays) as indicated in the
figure legends. A value of p = 0.05 was considered sig-
nificant, unless otherwise indicated.
For the ANOVA, the overall p value reported is reflec-
tive of the difference between the average proliferation
of Tregs using LRRC32 as an independent variable while
controlling for the individual assays as well as the titra-
tion. The R
2 value represents the amount of variability
in the ANOVA analysis that is accounted for by the pre-
sence or absence of LRRC32 on the surface of a Treg,
the individual assays, as well as the titration.
Results
Lrrc32 Is Preferentially Expressed in Tregs
A preliminary microarray analysis demonstrated upregu-
lated Lrrc32 gene expression in Tregs [9]. To confirm
these findings, we performed RT PCR analysis examin-
ing LRRC32 mRNA expression in sorted subpopulations
of CD25-expressing cells as depicted (Figure 1a) repre-
senting 1.5% of the CD4
+ cell population with the high-
e s te x p r e s s i o no fC D 2 5( C D 2 5
hi++), 2-3% of the CD4
+
cell population with high expression of CD25 (CD25
hi+),
17-20% of the CD4
+ cell population with reduced
expression of CD25 (CD25
mid), or no expression of
CD25 (CD25
-). These analyses revealed that Lrrc32
expression increased with surface CD25 expression in a
manner similar to Foxp3 expression (Figure 1b), con-
firming that Lrrc32 is preferentially expressed in Tregs.
To confirm that LRRC32 is specifically upregulated in
activated Tregs,w ec o m p a r e dt h es u r f a c ee x p r e s s i o no f
LRRC32 in the CD25
hi population and the CD25
- Teff
population of CD4
+ cells stimulated overnight with plate
bound anti-CD3 and soluble anti-CD28 and found that
LRRC32 is preferentially expressed on the surface of
activated Tregs but not activated Teffs (Figure 1c), in
accordance with a previous study [10]. Furthermore, in
accordance with this previous study, we also confirmed
that surface LRRC32 is present on sorted CD4
+CD25
hi
Tregs representing 5% of the CD4
+ cell population with
the highest expression of CD25 (i.e. including both the
CD25
hi++ and CD25
hi+ subgroups described above, Fig-
ure 1d, surface expression, stimulated, bottom left panel
set) that had been activated for 2 weeks with beads
coated with anti-CD28 and anti-CD3 but not on unsti-
mulated sorted CD4
+CD25
hi Tregs (Figure 1d, surface
expression, unstimulated, top left panel set) [10]. A low
intracellular expression of LRRC32 in resting sorted
CD4
+CD25
hi Tregs was noted (Figure 1d, permeabilized
expression, unstimulated, top right panel set). This sug-
gests that low levels of LRRC32 may be sequestered in
Tregs or might require additional processing prior to sur-
face expression. Increased expression of LRRC32 could
be seen in activated CD4
+CD25
hi sorted Tregs that had
been permeabilized (Figure 1d, permeabilized expres-
sion, stimulated, bottom right panel set) and was higher
than that seen on the surface only (Figure 1d, surface
expression, stimulated, bottom left panel set), as would
be expected for a surface protein that is initially pro-
duced intracellularly upon cell activation before traffick-
ing to the cell surface.
Lrrc32 Is Cleaved After Processing
Sequence analysis of murine LRRC32 predicted that
LRRC32 would be expressed as a transmembrane pro-
tein [6]. We analyzed the sequence of human LRRC32
using the transmembrane domain prediction server at
Stockholm Bioinformatics Center with a dense align-
ment method and confirmed the existence of a putative
19 amino acid transmembrane domain incorporating
residues 628 through 646 (data not shown), in agree-
ment with prior reports that this protein was expressed
at the cell surface [10,11]. Using the SignalP 3.0 server,
we also identified a putative 17 amino acid signal pep-
tide sequence and cleavage site between residues 17 and
18 (Figure 2a), consistent with the requirement for a sig-
nal peptide to be present in a protein destined for
expression at the cell surface [24]. To further under-
stand protein processing and surface expression of
human LRRC32, we generated LRRC32 constructs
incorporating green fluorescent protein (GFP) at either
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Page 6 of 15Figure 2 LRRC32 contains an N-terminal signal peptide and a transmembrane region. a) Analysis of the amino acid sequence of LRRC32
by SignalP 3.0 software predicted a putative N-terminal cleavage site between alanines 17 and 18. Alternative potential cleavage sites are
predicted and indicated as vertical solid lines on amino acids 19, 20, and 22. b) To address the actual cleavage site, N-terminal and C-terminal
GFP-tagged constructs were designed as depicted and generated to facilitate further analysis of surface expression and cleavage. SP = signal
peptide. TM = transmembrane region. GFP = green fluorescent protein. Arrow = putative cleavage site. c) Anti-GFP immunoblot analysis of total
lysates from C-and N- terminal expressing clones revealed 99 kD (29 kD GFP + 70 kD LRRC32) and 31 kD (29 kD GFP + 2 kD LRRC32 signal
peptide) fusion proteins respectively. Expected sizes of uncleaved fusion proteins, based upon predicted protein sequences, are shown in
parentheses. The difference in protein size between the C- and N-terminal fusion proteins confirms a cleavage site in the N-terminus of the
protein between alanines 17 and 18.
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the tagged signal peptide or the mature protein, respec-
tively (Figure 2b). Using anti-GFP antibodies, we exam-
ined total lysates from HEK-transfected C- and N-
terminus tagged LRRC32-expressing clones (Figure 2c).
Here, we show that 99kD (29 kD GFP+70 kD LRRC32)
and 31 kD (29 kD GFP+2 kD LRRC32) fusion proteins,
respectively, are generated in HEK transfectants overex-
pressing LRRC32, consistent with a cleaved N-terminus
signal peptide generated prior to surface expression of
LRRC32.
Lrrc32 on Transfected HEK293 Cells Is Expressed at the
Cell Surface Regardless of Stimulation
Although Tregs appear to require activation prior to
expressing LRRC32 on their surface, the same is not
true for transfected cell lines such as HEK293,a n dt h e
use of the HEK293 cell line allowed us to easily study
factors affecting the surface expression of LRRC32 in a
system that would not require constant T cell isolation
and activation [10,11,25]. We used C- and N-terminal
GFP-tagged LRRC32 (C-GFP/LRRC32 and N-GFP/
LRRC32, respectively) expressing HEK293 cell clones for
surface biotinylation and analysis. Following surface bio-
tinylation, cell lysates were prepared and anti-GFP anti-
bodies were used to immunoprecipitate the fusion
proteins. Precipitated protein was transferred to a PVDF
membrane. The membrane was then probed for biotin
using streptavidin-HRP (Figure 3a, left panel) or for
GFP using an anti-GFP antibody (Figure 3a, right
panel). Our results demonstrate biotinylated surface pro-
tein only in C-GFP/LRRC32-expressing clones (Figure
3a, left panel, rightmost lane), consistent with both sur-
face membrane expression of LRRC32 and intracellular
N-terminal processing (removal of the GFP-N-terminal
signal peptide) prior to membrane localization. Probing
the membrane with anti-GFP (Figure 3a, right panel)
demonstrates the surface and intracellular portions of
LRRC32 after cleavage.
Confocal studies with C-terminal GFP-tagged LRRC32
(C-GFP/LRRC32)-transfected HEK293 cells confirm that
GFP expression is found on the cell surface without sti-
mulation, in accordance with predictions that LRRC32
would be found on the cell surface (Figure 3b, fourth
row, right column). In contrast, N-terminal GFP-tagged
LRRC32 (N-GFP/LRRC32)-transfected HEK293 cells
exhibit GFP expression diffusely within cells, and GFP
expression is not concentrated at cell surfaces, presum-
ably since the GFP-tagged cleaved signal peptide of N-
GFP/LRRC32 remains intracellularly after cleavage, prior
to the translocation of the mature LRRC32 protein to
the cell surface (Figure 3b, third row, right column).
Antibody staining of surface LRRC32 confirmed that
mature C-GFP/LRRC32 and N-GFP/LRRC32 traffic to
Figure 3 LRRC32 is a cell surface protein.a )C - a n dN -t e r m i n u s
GFP-tagged LRRC32 expressing HEK293 cell clones were surface
biotinylated, and cell lysates were immunoprecipitated using
antibody specific for GFP or using normal rabbit serum (NRS) as a
control (left and right panels). Protein lysates were then
electrophoresed, transferred to membrane PDVF, and probed for
the presence of biotinylation using streptavidin-HRP (left panel
only). Blots were also probed with anti-GFP (right panel only). b)
Confocal analysis of untransfected (top row) HEK293 cells, C-GFP/
CAT-transfected HEK293 cells (second row), N-GFP/LRRC32-
transfected HEK293 cells (third row), C-GFP/LRRC32-transfected
HEK293 cells (fourth row), and C-GFP/LRRC32ΔSP-transfected HEK293
cells (last row); Green = GFP, Red = anti-LRRC32 antibody, Blue =
nuclear counterstain. The left column shows anti-LRRC32 only. The
right column shows GFP only. The middle column shows the
merged composite confocal picture (anti-LRRC32 + GFP) with the
nuclear counterstain.
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column). Our untransfected control cell line did not
express GFP or LRRC32 staining, as expected (Figure
3 b ,t o pr o w ) .F u r t h e r m o r e ,o u rC - t e r m i n a lG F P - t a g g e d
chloramphenicol acetyltransferase (C-GFP/CAT) control
cell line did not express LRRC32 staining, as expected
(Figure 3b, second row).
A putative signal peptide region corresponding to the
first 17 amino acids of Lrrc32 is required for surface
protein expression of Lrrc32
Since signal peptides are generally necessary to direct
surface expression of proteins, we next decided to see
whether deletion of the putative signal peptide region
would inhibit surface expression of LRRC32 [26-28].
HEK293 cells transfected with a C-terminus GFP-tagged
LRRC32 construct lacking the signal peptide (C-GFP/
LRRC32ΔSP) did not express surface LRRC32 by confo-
cal microscopy (Figure 3b, bottom row). Furthermore,
they did not express surface LRRC32 by flow cytometry
but were GFP positive, compared to HEK293 cells trans-
fected with the full length C-terminus GFP-tagged
LRRC32 construct, expressing both GFP and surface
LRRC32 (Figure 4a). Control untransfected cells did not
express GFP or surface LRRC32, as expected (Figure 4a,
leftmost panel).
Given the absence of surface expression of LRRC32 in
cells transfected with C-GFP/LRRC32ΔSP, we concluded
that the signal peptide portion of LRRC32 was critical
for surface expression of LRRC32. It was unclear, how-
ever, whether the absence of surface expression of
LRRC32 was due to intracellular sequestration of
LRRC32. We therefore conducted a western blot analy-
sis of lysates from HEK293 cells transfected with our
various constructs using an anti-LRRC32 antibody. Our
results showed that while LRRC32 can be detected in
cell lysates from cells transfected with full-length
LRRC32 constructs (C-GFP/LRRC32 and N-GFP/
LRRC32 at 99 and 70 kD, respectively), LRRC32 could
not be detected in cell lysates of HEK293 cells trans-
fected with the C-GFP/LRRC32ΔSP, suggesting that
LRRC32 is either produced at levels that were undetect-
able or is rapidly broken down following translation
(Figure 4b).
To confirm that Lrrc32 was being transcribed, we uti-
lized RT-PCR to analyze mRNA from lysates of HEK293
cells transfected with our various constructs. Our analy-
sis showed that Lrrc32 mRNA was detected in the C-
GFP/LRRC32 as well as the C-GFP/LRRC32ΔSP-trans-
fected HEK293 cell lysates (Figure 4c, left panel). In
contrast, untransfected HEK293 cells as well as the con-
trol C-terminus tagged chloramphenicol acetyltransfer-
ase (C-CAT)-transfected HEK293 cell lysates had
undetectable levels of Lrrc32 mRNA. Furthermore, as
expected, GFP expression was observed in all of the
HEK293 transfected cells examined (Figure 4c, right
panel). As we utilized stable clones derived from sorted
single cells with the highest GFP expression, as
described above, the different efficiencies of C-GFP/
LRRC32 vs. C-GFP/LRRC32ΔSP may be due to differen-
tial stability/integration of the plasmids in the selected
clones. Furthermore, it is possible that the signal peptide
mutant may be less stable, and as a result, cells trans-
fected with GFP/LRRC32ΔS Pm a yc o m p e n s a t eb yp r o -
ducing more mRNA to produce more protein.
Characterization of CD62L expression and functional
status of Lrrc32
+ and Lrrc32
- naturally-occurring freshly
isolated human Tregs
Using polyclonal activation via the TCR in combination
with anti-CD28 co-stimulation, we confirmed that
LRRC32 is expressed on the surface of naturally-occur-
ring freshly-isolated activated Tregs compared to unsti-
mulated Tregs (24.02% ± 1.73% (n = 6) vs. 2.30% ±
1.05% (n = 6), data not shown), respectively. We subse-
quently confirmed that surface LAP expression is also
observed in this cell population following activation
with plate-bound anti-CD3 and soluble anti-CD28, in
agreement with a recently published report (Figure 5a)
[11].
To date, no single surface marker is sufficient for
identifying naturally-occurring Tregs. In order to address
the expression of LRRC32 in the context of previously
described surface markers, we analyzed LRRC32
+ and
LRRC32
- subsets of CD4
+CD25
hiFoxP3
+LRRC32
+ Tregs,
as well as unactivated Tregs, with respect to the surface
co-expression of CD62L, CD45RO, CD69, GITR,
CTLA4, and HLA-DR (Figures 5b and 5c). Stimulated
Tregs demonstrated expected increases in the surface
expression of GITR, CD69, and CTLA4. Of interest,
however, stimulated LRRC32
+ Tregs exhibited less
CD62L and CD45RO than resting and stimulated
LRRC32
- Tregs, suggesting that LRRC32
+ Tregs may
represent a subset of activated or differentiated Tregs.
To address whether or not functional differences in
LRRC32
+ and LRRC32
- subsets of naturally-occurring
freshly isolated Tregs exist, we examined the suppressive
capacity of LRRC32
+ and LRRC32
- Tregs. Given previous
reports that transfection of Lrrc32-bearing constructs
into “pre-regulatory T cells” could induce them to upre-
gulate FoxP3 expression, we hypothesized that the
LRRC32
+ subset of naturally-occurring freshly-isolated
CD4
+CD25
hi Tregs would be more suppressive than the
LRRC32
- subset of CD4
+CD25
hi Tregs [8]. As described
above, our data demonstrates that LRRC32 expression
comports with FoxP3
+ expression. Therefore, we first
sorted CD25
hi CD4
+-purified cells and then activated
these and sorted again for Tregs expressing surface
Chan et al. BMC Biochemistry 2011, 12:27
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+ or LRRC32
- Tregs were then
used in mixed lymphocyte response assays to assess the
relative suppressive capabilities of each isolated popula-
tion of Tregs. Our results confirmed that naturally-occur-
ring freshly-isolated LRRC32
+ Tregs are more suppressive
than LRRC32
- Tregs (Figure 5d), exhibiting significant
increases in suppression at Treg:Teff ratios of 1:4, 1:8,
and 1:16 (p = 0.0324, 0.0142, and 0.0430, respectively).
Discussion
The isolation of naturally-occurring functional Tregs will
be a prerequisite for successful adoptive immunotherapy
Figure 4 A 17 AA signal peptide is required for the cell surface expression of LRRC32. a) Untransfected HEK293 cells or cells transfected
with either C-terminus GFP-tagged LRRC32 or C-terminus GFP-tagged LRRC32 with a deleted signal peptide region were analyzed by flow
cytometry for surface expression of LRRC32 or GFP expression. b) Anti-LRRC32 immunoblot analysis of total lysates from C-and N- terminus GFP-
tagged LRRC32 expressing clones revealed intact LRRC32 expression at 99 kD (fusion protein: 29 kD GFP + 70 kD LRRC32) and 70 kD,
respectively. However, immunoblot analysis of total lysates from C- terminus GFP-tagged LRRC32 expressing clones lacking an intact signal
peptide did not detect the presence of LRRC32 (rightmost lane). c) RT-PCR analysis of HEK293 cell lysates utilizing untransfected, C-CAT, C-
terminus GFP-tagged LRRC32, or C-terminus GFP-tagged LRRC32 lacking an intact signal peptide was performed using primers for Lrrc32 (left
panel) or GFP (right panel).
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+ CD4
+CD25
hiFoxP3 Tregs appear to be more potent suppressors than LRRC32
- CD4
+CD25
hiFoxP3 and exhibit decreased
CD62L upon activation. a) Expression of LRRC32 and LAP in CD4+ T cells rested overnight (top panel) or stimulated with plate bound anti-CD3
and soluble anti-CD28 (bottom panel). Tregs were selected from the top 5% CD25-expressing and FoxP3
+ populations, as previously described.
Confirmation of activation by expression of the surface markers CD40L and CD69 are also shown (top of each panel). b) The expression patterns of
various Treg and activation surface markers (CD62L, CD69, GITR, CTLA4, CD45RO, and HLA-DR) in FoxP3
+ and LRRC32
+-gated populations of CD25
hi
cells were studied using flow cytometry. Stimulated CD4
+FoxP3
+CD25
hi Tregs (top panel) & unstimulated CD4
+FoxP3
+CD25
hiTregs (bottom panel). c)
Composite summary of phenotypic analysis of unstimulated LRRC32
-CD4
+CD25
hiFoxP3
+ Tregs and stimulated LRRC32
+ and LRRC32
- CD4
+CD25
hiFoxP3
+ Tregs. Black bars = unstimulated LRRC32
- Tregs. Dark grey bars = stimulated LRRC32
- Tregs. Light grey bars = stimulated LRRC32
+ Tregs.
Data are expressed as the mean ± SEM from 3 individuals. Heteroscedastic variances and an independent t-test comparing stimulated LRRC32
+ and
LRRC32
- subsets were used for calculations of the p values which are reported along the x-axis, below each surface marker (*). d) CD25
hi cells were
sorted and activated overnight using anti-CD3-coated plates and soluble anti-CD28 (1 microgram/ml). Cells were then resorted based upon LRRC32
expression. The suppressive capacities of these LRRC32
+ and LRRC32
- Tregs were subsequently tested in a mixed lymphocyte reaction utilizing
syngeneic effectors (Teff, 20,000/well) and allogenic antigen presenting cells (50,000/well). Treg:Teff ratios are depicted above. Data summarize 3
independent experiments. Results are expressed as the mean ± SEM. p = 0.0001 and R
2 = 0.7244. Absolute proliferation values for the 3
experiments were as follow: Teffs alone: average of 31094 cpm to average of 47483 cpm (at least 6 replicates per assay), background: average of 24
cpm to 35 cpm (at least 6 replicates per assay); Treg:Teff ratio of 1:1: 89 cpm to 346 cpm. When titrating Tregs vs. Teffs, 3 replicates were performed at
each titration for the LRRC32
+ and LRRC32
- Tregs except for in one assay set in which there was limited number of LRRC32
+ Tregs. In this case, only
one replicate was performed at the 1:1 and 1:2 titrations, and two replicates were performed for the other titrations (0:1, 1:4, 1:8, and 1:16). We
performed 3 replicates for each titration utilizing the LRRC32
- Tregs.
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models have demonstrated proof of concept that iso-
lated Tregs can be used as therapy for several autoim-
mune disorders [29-31]. The isolation of functional Tregs
in humans, however, is problematic, in part due to a
paucity of specific surface markers. In this report, we
demonstrate direct evidence of the surface expression of
LRRC32 on freshly-isolated, naturally-occurring, and
non-expanded CD4+ CD25
hi human Tregs following
TCR activation. We furthermore have characterized
LRRC32 processing and demonstrate that sorted subsets
of freshly isolated Tregs bearing this marker appear more
suppressive than subsets lacking this marker.
Previous studies have shown that constitutive over-
expression of Lrrc32 in CD25
- Teffs can lead to Foxp3
upregulation and that these cells subsequently acquire a
suppressive phenotype [8,25]. Similarly, overexpression
of Foxp3 has been shown to result in increased mRNA
levels of Lrrc32, suggesting positive feedback between
FoxP3 and LRRC32 [8,25]. Although other groups have
shown that surface LRRC32 is highly elevated in
expanded activated Tregs compared to CD25
- Teffs,w e
demonstrate here that low levels of intracellular
LRRC32 are detectable in naturally-occurring freshly-
isolated unstimulated Tregs (Figure 1d) [8,25].
Previous studies utilizing an antibody generated
against amino acids 296-308 of LRRC32 failed to detect
LRRC32 on transfected Jurkat cells or on native CD4
+CD25
hiTregs [25]. However, as shown here, a commer-
cially available anti-LRRC32 monoclonal antibody does
recognize surface LRRC32 on transfected HEKs and
naturally-occuring freshly-derived Tregs that have under-
gone stimulation. Furthermore, it detects low intracellu-
lar expression of LRRC32 in naturally-occurring freshly-
derived Tregs. Failure to detect surface LRRC32 by the
antibody raised against peptide 296-308 may be due to
competitive occupation by a ligand as this region of
LRRC32 corresponds to a loop and has been hypothe-
sized to correspond to a ligand binding site [25]. One
proposed ligand that could occupy this site may be LAP,
as recently published work has demonstrated an interac-
tion between LAP and LRRC32 [11,13,32]. If residues
296-308 of LRRC32 act as a binding site for LAP, occu-
pation of this site may account for the failure of pre-
vious LRRC32-specific antibodies to recognize surface
LRRC32 expression.
T od e t e r m i n ei fL R R C 3 2i ss e q u e s t e r e di nT regs,w e
examined the intracellular expression of LRRC32 in
naturally-occurring freshly-isolated unstimulated Tregs
by flow cytometry. We show that unstimulated Tregs
contain low levels of intracellular LRRC32 protein.
However, coupled with our RT-PCR studies showing
high levels of Lrrc32 mRNA in unstimulated Tregs rela-
tive to Teffs, these data suggest that post-transcriptional
mechanisms may play a role in controlling LRRC32 pro-
duction and expression in non-activated Tregs.S u c h
post-transcriptional controls may be diminished upon
stimulation via TCR/CD28 signaling, as indeed, upon
stimulation, evidence of increased intracellular LRRC32
protein was evident in Tregs as assessed by flow cytome-
try (Figure 1d).
In addition, our signal peptide deletion construct stu-
dies reveal that the putative signal peptide in LRRC32 is
critical for the cell surface expression of LRRC32, con-
sistent with other reports that signal peptides are neces-
sary for surface protein expression [33]. Our data
showing that LRRC32ΔSP is transcribed (Figure 4c) but
not detected intracellularly (Figure 4b) suggest that
LRRC32ΔSP is rapidly broken down in the cytosol or is
not translated at detectable levels following transcrip-
tion. However, mechanisms for the rapid degradation of
misfolded proteins exist to maintain cell viability, and as
such, cytosolic LRRC32ΔSP, unable to enter the endo-
plasmic reticulum owing to the lack of a signal peptide,
may be translated but rapidly degraded afterwards by
processes such as ubiquitination [34].
Finally, using freshly isolated, non-expanded CD4
+CD25
hiLRRC32
+ Tregs, we show that such cells expressing
surface LRRC32 appear to be functionally more suppres-
sive than CD4
+CD25
hiLRRC32
- Tregs. Previous reports
have shown that upon activation of Teffs, surface CD62L is
usually decreased [35-37]. However, Tregs normally main-
tain CD62L expression and functional phenotype [38].
Furthermore, previous reports have shown that CD62L
+CD4
+CD25
hi Tregs are more suppressive than their
CD62L
- counterparts [39,40].We show here that expres-
sion of surface CD62L appears to decrease significantly on
LRRC32
+ Tregs compared to LRRC32
- Treg populations.
Differences in CD62L processing may be responsible
for the observed difference in CD62L expression
between LRRC32
+ and LRRC32
- activated Tregs.I th a s
been shown that 90% of CD62L is rapidly cleaved from
the surface within 4 hours of T cell activation prior to
increasing over the next 48 hours, due to enhanced
message stability, before ultimately decreasing due to
downregulation of gene transcription [41]. Furthermore,
it has been reported that CD62L is rapidly shed in T
cells, including Tregs, after activation [42,43]. In accor-
dance, our data show that unstimulated LRRC32
- CD4
+CD25
hiFoxP3
+ Tregs expressed more surface CD62L
than stimulated LRRC32
+ or LRRC32
- CD4
+CD25
hi-
FoxP3
+ Tregs. However, upon activation, decreases in
surface CD62L expression of LRRC32
+ versus LRRC32
-
cells were noted, suggesting that LRRC32
+ cells are
more activated compared to LRRC32
- Tregs.G i v e nt h a t
an overnight stimulation is sufficient to induce LRRC32
expression on the cell surface of Tregs,w ec h o s et h i sa s
our timepoint for phenotypic analysis. However, altering
Chan et al. BMC Biochemistry 2011, 12:27
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Treg marker expression.
Activated Tregs that express LRRC32 may also repre-
sent a distinct population of more highly activatable
Tregs compared to LRRC32
- Tregs [41]. Indeed, our phe-
notypic studies using LRRC32
+ and LRRC32
- subsets of
Tregs in the context of CD62L expression would appear
to support the interpretation that LRRC32
+ Tregs, rela-
tive to LRRC32
- Tregs, are more prone to activation, as
shown by increased cleavage of surface CD62L, and that
this more highly activated state may translate into
increased suppressive activity. Notably, although only a
fraction of Tregs expressed LRRC32 upon activation
overnight, these cells appeared to be more functionally
suppressive than their LRRC32
- counterparts.
Most natural FoxP3
+ adult Tregs are CD45RO
+,a n d
the expression of CD45RO is typically a marker of T
cell activation [44,45]. As LRRC32
+ Tregs appear to be
more suppressive than LRRC32
- Tregs, it is possible that
lower expression of CD45RO on LRRC32
+ Tregs relative
to LRRC32
- Tregs may be due to increased auto-suppres-
sive activity by LRRC32
+ Tregs compared to LRRC32
-
Tregs. As noted above, stimulated Tregs demonstrated
expected increases in the surface expression of GITR,
CD69, and CTLA4. GITR, or glucocorticoid-induced
tumor necrosis factor receptor, was originally shown to
be highly expressed on unactivated Tregs but relative to
Teffs, and its expression was increased upon cell activa-
tion [46-48]. It appears that GITR is a co-stimulatory
molecule, and although it is preferentially expressed on
CD25
hi cells, it is also expressed at lower levels on Teffs,
and upon activation, Teffs can also upregulate GITR
[48,49]. Hence, the use of GITR as a specific marker for
Tregs appears to be limited. CD69 has been described in
the context of a CD69
+CD4
+CD25
- Treg subset that
does not express Foxp3 but does express surface-bound
TGF-b1 in an ERK-dependent manner [50]. Normally,
CD69 is upregulated upon T cell activation, and thus
expected on our Tregs [50-52]. Since LRRC32 also binds
LAP, thereby helping to concentrate TGF-b1 at the cell
surface, it is interesting to speculate whether CD69 in
Tregs may play a role in helping to upregulate TGF-b1
surface expression in the context of LRRC32 when the
latter is available. Although our data did not find any
significant differences in the CD69 expression in stimu-
lated LRRC32
+ and LRRC32
- Treg subsets (Figure 5c), it
is possible that part of the reason for the observed dif-
ference in suppressive activity between the LRRC32
+
and LRRC
- Treg subsets may be in part due to synergy
between CD69 and LRRC32 via increased surface
expression of TGF-b1. CTLA4, or cytotoxic T lympho-
cyte antigen-4, can inhibit Teff activation via 1) binding
B7.1 and B7.2, thereby depriving CD28 on Teffs of the
ability to bind these co-stimulatory ligands, 2) inhibiting
IL-2 transcription and progression of cells through the
cell cycle via inhibition of cyclin D3, cdk4, and cdk6
production, and 3) decreasing the amount of time the
TCR is engaged [53-57]. As we did not see any signifi-
cant differences in CTLA4 expression in the LRRC32
+
and LRRC32
- Treg subsets, we do not have data to sug-
gest that differences in CTLA4 expression might have
contributed to the observed differences in suppressive
function in the LRRC32
+ and LRRC32
- Treg subsets.
Clearly, the results in this set of experiments raise many
more interesting questions and suggest that the role of
LRRC32 in the context of these other cell activation
markers is complex.
Previous studies examining LRRC32 and T cell regula-
tion have utilized Teffs transfected with constructs con-
taining either wildtype Lrrc32 or Lrrc32 lacking leucine
rich repeat regions, the signal peptide, the cytoplasmic
domain, or Lrrc32 with a mutated cytoplasmic residue
postulated to be part of a PDZ domain and thus thought
to bind an intracellular protein [8,25]. These experi-
ments were performed to address how LRRC32 may be
processed and ultimately function in Treg cells. PDZ
domain mutation studies have suggested that the intra-
cellular portion of LRRC32 is critical for surface expres-
sion, and other studies examined the LRRC32 deletion
mutants in the context of downstream effector mole-
cules such as FoxP3 [8,25]. These studies concluded
that because FoxP3 expression was markedly decreased
upon deletion of the leucine rich regions or the signal
peptide, these regions were critical for LRRC32 function
[8,25]. However, these studies never demonstrated actual
cleavage of the putative signal peptide [8]. Here, we
demonstrate via immunoprecipitation and confocal stu-
dies that LRRC32 encodes a signal peptide that is
cleaved, and upon cleavage, allows mature LRRC32 to
reach the cell surface.
It is likely that the LRRC32 signal peptide is cleaved
from the newly translocated preprotein by type I eukar-
yotic endoplasmic reticulum signal peptidase, based
upon the amino acid sequence of LRRC32 [58]. The
initial amino acid sequence of LRRC32 incorporating a
charged N-terminal domain followed by a hydrophobic
domain is consistent with published reports of the con-
sensus motif for eukaryotic type I endoplasmic reticu-
lum signal peptidase [58,59]. Furthermore, the sequence
G-L-A at positions 15 though 17 of the preprotein is
consistent with the -3, -1 rule, stating that residues at
the -3 and -1 positions, relative to the cleavage site,
must be neutral and have small side chains [58].
Conclusions
In summary, we have demonstrated a cleaved signal
peptide site in LRRC32 is necessary for surface localiza-
tion of native LRRC32 following activation of naturally-
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that LRRC32
+ CD4
+CD25
hiFoxP3
+ Tregs express lower
levels of surface CD62L compared to LRRC32
- CD4
+CD25
hiFoxP3
+ Tregs, suggesting that LRRC32 expres-
sion may alter surface expression of other activation
markers of T cells such as CD62L. Finally, functional
data demonstrate that LRRC32
+ Tregs appear more sup-
pressive compared to LRRC32
- Tregs, suggesting that
LRRC32 surface expression may be useful as a marker
that selects for more potent Treg populations, although
our data suggest that the functional difference in sup-
pression between these two populations is not markedly
robust. Hence, LRRC32 selection may be most useful
when used in combination with other Treg markers [60].
Acknowledgements
DVC was supported by NIH 2T32AR007569-16A (Program Director: KDC) and
NIH 3P50AR055508-03S309 (DVC, TSM, and KDC). AKS was supported in part
by the Dermatology Foundation. This research was also supported by NIH
P30AR039750 (KDC). Flow cytometry was also supported by NIH
P30CA43703 awarded to the Case Comprehensive Cancer Center. The
authors wish to thank Christianne Sykes and Christy Malbasa, M.D. for their
efforts in helping to procure patient samples, David Soler, Ph.D. for help in
preparing cells, and Wendy Goodman, Ph.D. for critical review of the
manuscript.
Author details
1Previous Address: Department of Dermatology, University Hospitals Case
Medical Center and Case Western Reserve University, Cleveland, OH, 44106
USA.
2Department of Dermatology and Allergology, University of Szeged,
Szeged, Hungary.
3Department of Dermatology, University of Yamanashi,
Yamanashi, Japan.
4Statistical Sciences Core, Center For Clinical Investigation,
Case Western Reserve University, Cleveland, OH, 44106 USA.
5VA Medical
Center, Cleveland, OH, 44106 USA.
6Current Address: Ohio State University
Dermatology, 2012 Kenny Road, Columbus, OH, 43221, USA.
7Current
Address: Department of Dermatology, Indiana University School of Medicine,
550 N. University Blvd., Suite 3240, Indianapolis, IN, 46202, USA.
Authors’ contributions
DVC, AKS, ABY, JVM, JO, HS, and EG performed experiments represented in
this manuscript. DB provided statistical support. KDC, HS, and TSM provided
valuable designed the study. DVC, TSM, and KDC drafted the manuscript. All
authors read and approved the final manuscript.
Received: 26 October 2010 Accepted: 26 May 2011
Published: 26 May 2011
References
1. Bottcher RT, Pollet N, Delius H, Niehrs C: The transmembrane protein
XFLRT3 forms a complex with FGF receptors and promotes FGF
signalling. Nat Cell Biol 2004, 6(1):38-44.
2. Ollendorff V, Szepetowski P, Mattei MG, Gaudray P, Birnbaum D: New gene
in the homologous human 11q13-q14 and mouse 7F chromosomal
regions. Mamm Genome 1992, 2(3):195-200.
3. Ollendorff V, Noguchi T, deLapeyriere O, Birnbaum D: The GARP gene
encodes a new member of the family of leucine-rich repeat-containing
proteins. Cell Growth Differ 1994, 5(2):213-219.
4. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-
Lostanlen D, Kelley PM, Pebusque MJ, Theillet C, Birnbaum D, et al: Detailed
map of a region commonly amplified at 11q13–>q14 in human breast
carcinoma. Cytogenet Cell Genet 1997, 79(1-2):125-131.
5. Merscher S, Bekri S, de Leeuw B, Pedeutour F, Grosgeorge J, Shows TB,
Mullenbach R, Le Paslier D, Nowak NJ, Gaudray P, et al: A 5.5-Mb high-
resolution integrated map of distal 11q13. Genomics 1997, 39(3):340-347.
6. Roubin R, Pizette S, Ollendorff V, Planche J, Birnbaum D, Delapeyriere O:
Structure and developmental expression of mouse Garp, a gene
encoding a new leucine-rich repeat-containing protein. Int J Dev Biol
1996, 40(3):545-555.
7. Chang MX, Nie P, Xie HX, Sun BJ, Gao Q: Characterization of two genes
encoding leucine-rich repeat-containing proteins in grass carp
Ctenopharyngodon idellus. Immunogenetics 2005, 56(10):710-721.
8. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D: Identification of a
regulatory T cell specific cell surface molecule that mediates suppressive
signals and induces Foxp3 expression. PLoS ONE 2008, 3(7):e2705.
9. Somani A, Young A, Sugiyama H, Bookout A, Lam M, Cooper K,
McCormick T: Characterization of glycoprotein A repetition predominant
protein (GARP) identified as a novel gene marker of human CD4
+CD25high regulatory T cells (Treg). 2008 International Investigative
Dermatology Meeting 2008.
10. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D: Expression of
GARP selectively identifies activated human FOXP3+ regulatory T cells.
Proc Natl Acad Sci USA 2009, 106(32):13439-13444.
11. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM: GARP
(LRRC32) is essential for the surface expression of latent TGF-beta on
platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA
2009, 106(32):13445-13450.
12. Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM: Selective
expression of latency-associated peptide (LAP) and IL-1 receptor type I/II
(CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows
for their purification from expansion cultures. Blood 2009,
113(21):5125-5133.
13. Stockis J, Colau D, Coulie PG, Lucas S: Membrane protein GARP is a
receptor for latent TGF-beta on the surface of activated human Treg. Eur
J Immunol 2009, 39(12):3315-3322.
14. Nakamura K, Kitani A, Strober W: Cell contact-dependent
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by
cell surface-bound transforming growth factor beta. J Exp Med 2001,
194(5):629-644.
15. Takahashi T: Immunologic self-tolerance maintained by CD25+CD4+
regulatory T cells constitutively expressing cytotoxic T lymphocyte-
associated antigen 4. J Exp Med 2000, 192:303-310.
16. Nishizuka Y, Sakakura T: Thymus and reproduction: sex-linked dysgenesia
of the gonad after neonatal thymectomy in mice. Science 1969,
166:753-755.
17. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development
by the transcription factor Foxp3. Science 2003, 299:1057-1061.
18. Sakaguchi S: Immunologic self-tolerance maintained by activated T cells
expressing IL-2 receptor [alpha]-chains (CD25). J Immunol 1995,
155:1151-1164.
19. Schwartz RH: Natural regulatory T cells and self-tolerance. Nat Immunol
2005, 6(4):327-330.
20. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development
and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003,
4:330-336.
21. Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in
CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
22. Bachmann MF: Cutting edge: lymphoproliferative disease in the absence
of CTLA-4 is not T cell autonomous. J Immunol 1999, 163:1128-1131.
23. Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR,
McCormick TS, Cooper KD: Dysfunctional Blood and Target Tissue CD4
+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying
Unrestrained Pathogenic Effector T Cell Proliferation. J Immunol 2005,
174(1):164-173.
24. Dyrløv Bendtsen J, Nielsen H, von Heijne G, Brunak S: Improved Prediction
of Signal Peptides: SignalP 3.0. Journal of Molecular Biology 2004,
340(4):783-795.
25. Probst-Kepper M, Geffers R, Kroger A, Viegas N, Erck C, Hecht HJ,
Lunsdorf H, Roubin R, Moharregh-Khiabani D, Wagner K, et al: GARP: a key
receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med
2009, 13:13.
26. Emanuelsson O, Brunak S, von Heijne G, Nielsen H: Locating proteins in
the cell using TargetP, SignalP and related tools. Nat Protoc 2007,
2(4):953-971.
Chan et al. BMC Biochemistry 2011, 12:27
http://www.biomedcentral.com/1471-2091/12/27
Page 14 of 1527. Gilmore R, Blobel G, Walter P: Protein translocation across the endoplasmic
reticulum. I. Detection in the microsomal membrane of a receptor for the
signal recognition particle. J Cell Biol 1982, 95(2 Pt 1):463-469.
28. Gilmore R, Walter P, Blobel G: Protein translocation across the
endoplasmic reticulum. II. Isolation and characterization of the signal
recognition particle receptor. J Cell Biol 1982, 95(2 Pt 1):470-477.
29. La Cava A: T-regulatory cells in systemic lupus erythematosus. Lupus
2008, 17(5):421-425.
30. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A,
Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of
the CD4+CD25+ immunoregulatory T cells that control autoimmune
diabetes. Immunity 2000, 12(4):431-440.
31. Janine LC, Nicholas JR, Kevin JM, Holm HU, Fiona P: Regulatory T cells and
intestinal homeostasis. Immunological Reviews 2005, 204(1):184-194.
32. Tran DQ, Shevach EM: Therapeutic potential of FOXP3+ regulatory T cells
and their interactions with dendritic cells. Human Immunology 2009,
70(5):294-299.
33. Couvineau A, Rouyer-Fessard C, Laburthe M: Presence of a N-terminal
signal peptide in class II G protein-coupled receptors: crucial role for
expression of the human VPAC1 receptor. Regulatory Peptides 2004,
123(1-3):181-185.
34. Goldberg AL: Protein degradation and protection against misfolded or
damaged proteins. Nature 2003, 426(6968):895-899.
35. Mascarell L, Truffa-Bachi P: T lymphocyte activation initiates the
degradation of the CD62L encoding mRNA and increases the
transcription of the corresponding gene. Immunol Lett 2004, 94(1-
2):115-122.
36. Gerberick GF, Cruse LW, Miller CM, Sikorski EE, Ridder GM: Selective
Modulation of T Cell Memory Markers CD62L and CD44 on Murine
Draining Lymph Node Cells Following Allergen and Irritant Treatment.
Toxicology and Applied Pharmacology 1997, 146(1):1-10.
37. Gomes-Pereira S, Rodrigues OR, Santos-Gomes GM: Dynamics of CD62L/
CD45RB CD4+ and CD8+ lymphocyte subsets in hepatic and splenic
tissues during murine visceral leishmaniasis. Immunology Letters 2004,
95(1):63-70.
38. Strauss L, Bergmann C, Whiteside TL: Functional and phenotypic
characteristics of CD4+CD25highFoxp3+ Treg clones obtained from
peripheral blood of patients with cancer. Int J Cancer 2007,
121(11):2473-2483.
39. Lepault F, Gagnerault MC: Characterization of Peripheral Regulatory CD4+
T Cells That Prevent Diabetes Onset in Nonobese Diabetic Mice. J
Immunol 2000, 164(1):240-247.
40. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Mao M, Ding Y, Bromberg JS:
CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive
and proliferative potential. Am J Transplant 2004, 4(1):65-78.
41. Chao CC, Jensen R, Dailey MO: Mechanisms of L-selectin regulation by
activated T cells. J Immunol 1997, 159(4):1686-1694.
42. Guo Z, Jang MH, Otani K, Bai Z, Umemoto E, Matsumoto M, Nishiyama M,
Yamasaki M, Ueha S, Matsushima K, et al: CD4+CD25+ regulatory T cells in
the small intestinal lamina propria show an effector/memory phenotype.
Int Immunol 2008, 20(3):307-315.
43. Tang Q, Bluestone JA: The Foxp3+ regulatory T cell: a jack of all trades,
master of regulation. Nat Immunol 2008, 9(3):239-244.
44. Akbar AN, Terry L, Timms A, Beverley PC, Janossy G: Loss of CD45R and
gain of UCHL1 reactivity is a feature of primed T cells. J Immunol 1988,
140(7):2171-2178.
45. Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius E, Jackson SE,
Salmon M, Falciani F, Yong K, Rustin MH, et al: Different proliferative
potential and migratory characteristics of human CD4+ regulatory T
cells that express either CD45RA or CD45RO. J Immunol 2010,
184(8):4317-4326.
46. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M,
Byrne MC: CD4(+)CD25(+) immunoregulatory T cells: gene expression
analysis reveals a functional role for the glucocorticoid-induced TNF
receptor. Immunity 2002, 16(2):311-323.
47. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of
CD25(+)CD4(+) regulatory T cells through GITR breaks immunological
self-tolerance. Nat Immunol 2002, 3(2):135-142.
48. Ermann J, Fathman CG: Costimulatory signals controlling regulatory T
cells. Proc Natl Acad Sci USA 2003, 100(26):15292-15293.
49. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, Cobbold SP, Waldmann H:
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is
costimulatory for T cells. Proc Natl Acad Sci USA 2003,
100(25):15059-15064.
50. Han Y, Guo Q, Zhang M, Chen Z, Cao X: CD69+ CD4+ CD25- T cells, a
new subset of regulatory T cells, suppress T cell proliferation through
membrane-bound TGF-beta 1. J Immunol 2009, 182(1):111-120.
51. De Maria R, Cifone MG, Trotta R, Rippo MR, Festuccia C, Santoni A, Testi R:
Triggering of human monocyte activation through CD69, a member of
the natural killer cell gene complex family of signal transducing
receptors. J Exp Med 1994, 180(5):1999-2004.
52. Sancho D, Gomez M, Sanchez-Madrid F: CD69 is an immunoregulatory
molecule induced following activation. Trends Immunol 2005,
26(3):136-140.
53. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP: CTLA-4-
Mediated inhibition of early events of T cell proliferation. J Immunol
1999, 162(10):5813-5820.
54. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M,
Der SD, Kang J, Chambers CA: CD4+ regulatory T cells require CTLA-4 for
the maintenance of systemic tolerance. J Exp Med 2009, 206(2):421-434.
55. Ostrov DA, Shi W, Schwartz JC, Almo SC, Nathenson SG: Structure of
murine CTLA-4 and its role in modulating T cell responsiveness. Science
2000, 290(5492):816-819.
56. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ: CD80 (B7-1)
binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J
Exp Med 1997, 185(3):393-403.
57. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B,
Hogg N, Garside P, Rudd CE: Reversal of the TCR stop signal by CTLA-4.
Science 2006, 313(5795):1972-1975.
58. Tuteja R: Type I signal peptidase: An overview. Archives of Biochemistry
and Biophysics 2005, 441(2):107-111.
59. von Heijne G: The signal peptide. J Membr Biol 1990, 115(3):195-201.
60. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA,
Kapranov P, Gingeras TR, Fazekas de St Groth B, et al: CD127 expression
inversely correlates with FoxP3 and suppressive function of human CD4
+ T reg cells. J Exp Med 2006, 203(7):1701-1711.
doi:10.1186/1471-2091-12-27
Cite this article as: Chan et al.: Signal peptide cleavage is essential for
surface expression of a regulatory T cell surface protein, leucine rich
repeat containing 32 (LRRC32). BMC Biochemistry 2011 12:27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chan et al. BMC Biochemistry 2011, 12:27
http://www.biomedcentral.com/1471-2091/12/27
Page 15 of 15